The following is a press release issued by the California Department of Public Health:
California State Epidemiologist Dr. Erica Pan issued the following statement today advising providers that they can immediately resume the administration of lot 41L20A of the Moderna COVID-19 vaccine, which was temporarily paused on Sunday due to possible allergic reactions.
“Our highest priorities are to ensure that vaccines are safe and effective, and distributed equitably and efficiently,” said Dr. Pan.
“Out of an abundance of caution, we recommended that providers pause the distribution of Moderna COVID-19 vaccine lot 41L20A on Sunday evening. Yesterday, we convened the Western States Scientific Safety Review Workgroup and additional allergy and immunology specialists to examine the evidence collected. We had further discussions with the County of San Diego Department of Public Health, the FDA, CDC and manufacturer, and found no scientific basis to continue the pause. Providers that paused vaccine administration from Moderna Lot 41L20A can immediately resume.
“These findings should continue to give Californians confidence that vaccines are safe and effective, and that the systems put in place to ensure vaccine safety are rigorous and science-based. Members of my family who have qualified to receive the vaccine as health care workers or because of their age have already received the COVID-19 vaccine, and I encourage every Californian to get the vaccine when it’s their turn.”
Earlier Chapters
- At Least Two Hundred Doses of the Moderna Vaccine Batch Associated with Higher Than Usual Allergic Reactions Administered to Mendocino County Residents
- [UPDATED] Mendocino Public Health Determines One Hundred Doses of Discontinued Moderna Batch Were Administered at Mass Vaccination Event
- Approximately 100 Mendocino Coast Residents Administered Batch of Moderna Vaccines That Has Been Discontinued for Higher Than Usual Allergic Reactions; No Adverse Reactions Reported Locally
- After ‘Higher Than Usual’ Allergic Reactions, Officials Suggest Pausing the Use of Specific COVID-19 Vaccine Batch